JP2003516936A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516936A5
JP2003516936A5 JP2001534412A JP2001534412A JP2003516936A5 JP 2003516936 A5 JP2003516936 A5 JP 2003516936A5 JP 2001534412 A JP2001534412 A JP 2001534412A JP 2001534412 A JP2001534412 A JP 2001534412A JP 2003516936 A5 JP2003516936 A5 JP 2003516936A5
Authority
JP
Japan
Prior art keywords
particles
adjuvant
antigen
coated
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001534412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516936A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/025854 external-priority patent/WO2001032208A1/en
Publication of JP2003516936A publication Critical patent/JP2003516936A/ja
Publication of JP2003516936A5 publication Critical patent/JP2003516936A5/ja
Pending legal-status Critical Current

Links

JP2001534412A 1999-11-03 1999-11-03 アジュバント化遺伝子ワクチン Pending JP2003516936A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/025854 WO2001032208A1 (en) 1999-11-03 1999-11-03 Adjuvanted genetic vaccines

Publications (2)

Publication Number Publication Date
JP2003516936A JP2003516936A (ja) 2003-05-20
JP2003516936A5 true JP2003516936A5 (enExample) 2006-12-28

Family

ID=22273970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534412A Pending JP2003516936A (ja) 1999-11-03 1999-11-03 アジュバント化遺伝子ワクチン

Country Status (14)

Country Link
EP (1) EP1227840B1 (enExample)
JP (1) JP2003516936A (enExample)
CN (1) CN100333794C (enExample)
AT (1) ATE374622T1 (enExample)
AU (1) AU780448C (enExample)
CA (1) CA2389686A1 (enExample)
CY (1) CY1107845T1 (enExample)
DE (1) DE69937258T2 (enExample)
DK (1) DK1227840T3 (enExample)
ES (2) ES2294864T3 (enExample)
IL (2) IL149415A0 (enExample)
NZ (1) NZ518766A (enExample)
PT (2) PT1227840E (enExample)
WO (1) WO2001032208A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE460945T1 (de) * 1999-11-03 2010-04-15 Powderject Vaccines Inc Genetische adjuvanz-impfstoffe
BR0209854A (pt) * 2001-05-18 2004-06-08 Powderject Vaccines Inc Molécula de ácido nucléico recombinante, cassete de expressão, vetor, polipeptìdeo, composição de vacina, dispositivo de aceleração de partìcula, e, método para gerar uma resposta imune celular em um indivìduo
US7566478B2 (en) 2001-07-25 2009-07-28 Nantero, Inc. Methods of making carbon nanotube films, layers, fabrics, ribbons, elements and articles
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
US11207241B2 (en) 2013-03-15 2021-12-28 Phd Preventative Health Care And Diagnostics, Inc. Prefilled medication device, method of making and using the same
WO2020252263A1 (en) 2019-06-12 2020-12-17 Wisconsin Alumni Research Foundation Novel adjuvant for animal and human vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
WO1995019799A1 (en) * 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
ES2301175T3 (es) * 1996-02-09 2008-06-16 Smithkline Beecham Biologicals S.A. Vacunas contra el producto del gen 63 del virus de la varicela zoster.
WO1998035562A1 (en) * 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
AU6897098A (en) * 1997-04-14 1998-11-11 University Of Massachusetts Medical Center Saponin adjuvants in combination with dna vaccination
CN1285753A (zh) * 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
CU22740A1 (es) * 1998-09-07 2002-02-28 Ct Ingenieria Genetica Biotech Formulación de ácidos nucleicos y acemanano

Similar Documents

Publication Publication Date Title
EP1322287B1 (en) Microparticles for delivery of the heterologous nucleic acids
JP2025063030A5 (enExample)
Saroja et al. Recent trends in vaccine delivery systems: a review
O'Hagan et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines
O’Hagan et al. Microparticle-based technologies for vaccines
Moser et al. Virosomal adjuvanted antigen delivery systems
CN104027324B (zh) 一种可溶性微针疫苗贴片及其制备方法
Kaurav et al. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage
JP4601168B2 (ja) 吸着表面を有する微小粒子、それを作製する方法、およびその使用
EP2269642A2 (en) Hcv vaccine compositions
JP2001523729A5 (enExample)
JPH11500443A (ja) コクリエート送達ビヒクル
JP2001524533A (ja) 粒子状ワクチン組成物の経皮的送達
JP2003520824A (ja) 免疫変調用医薬組成物並びに抗原および免疫原性オリゴデオキシヌクレオチドおよびアジュバントとしてのポリカチオン性ポリマーを含むワクチンの調製
JP2003514872A5 (enExample)
Wang et al. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice
Xiang et al. Promising particle-based vaccines in cancer therapy
Plotkin Six revolutions in vaccinology
Newman et al. Immunological and formulation design considerations for subunit vaccines
Engler et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates
JP2004508065A5 (enExample)
Prashant et al. Nanoparticle based tailoring of adjuvant function: the role in vaccine development
CN117298264A (zh) 基于流感病毒ha蛋白和新冠病毒s蛋白的组合物和疫苗
JP2006502228A5 (enExample)
Ha et al. Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination